News
Grant Opportunities Announcement
Submit Letters of Intent by March 7, 2022 The Neuroendocrine Tumor Research Foundation (NETRF), Boston, Massachusetts, has released its 2022 Request for Applications. We invite
The 2021 Virtual NET Research Symposium – Summary/Recap
The fourteenth annual NETRF Research Symposium successfully concluded last month with over 300 registered virtual attendees participating from around the globe for the second year in a row. The meeting included nearly 60 talks and posters representing the cutting edge of NET research where investigators reported their latest data and discoveries to share and discuss with colleagues. This year posters were available for viewing over the three days preceding the two-day meeting, resulting in over 300 poster views and ample time for discussions. Over 95% of registrants attended the two-days of talks and live discussions while the recorded talks and posters were viewed by over 100 more attendees over the following week.
NETRF Announces Changes to its Board of Scientific Advisors
Dr. Thirlwell, the Mireille Gillings Professor of Cancer Genomics at the University of Exeter Medical School will assume the role in January of 2022. She is internationally renowned for advancing NET research, the clinical management of NETs and the integrated genomic analysis of cancer.
New Clinical Trial Explores Addition of Anti-Cancer Drug BAY 1895344 to Standard Chemotherapy
The phase 1a/1b clinical trial is being conducted in patients who have advanced small cell lung cancer, poorly differentiated neuroendocrine cancer, or pancreatic cancer. Satya Das, MD, MSCI, at Vanderbilt University Medical Center serves as principal investigator of the study, which is sponsored by the National Cancer Institute.
Firsty Family’s successful Moonlight Walk surpasses fundraising goal
The California family resumed an in-person event to raise money for NETRF in honor of wife and mother Julie Firsty.
Clinical Trial Focuses on Use of Lutetium 177 in Lung NETs
Promising clinical trial using Lutetium 177 in LungNETS.
Research Spotlight: Rodney Hicks, MD
Peptide receptor radionuclide therapy, or PRRT, has been available as a treatment option for some forms of neuroendocrine tumors – particularly for those NETs expressing the somatostatin receptor-2 (SSTR2) protein.
New Clinical Trial Focuses on Lutathera® in Adolescents with NETs
A phase II clinical trial has launched to study Lutathera® in adolescents with gastroenterpancreatic neuroendocrine tumors (GEP-NET), pheochromocyomas and paragangliomas (PPGLs).
NETRF Announces Changes to its Board of Scientific Advisors
The Neuroendocrine Tumor Research Foundation (NETRF) recently announced changes to the Board of Scientific Advisors (BOSA), extending its sincerest appreciation for the participation of Dung Thi Le, MD, and welcoming Jennifer Eads, MD
Biking for Debbie 2021
As another summer came to a close, the riders of Biking for Debbie were on the road again!